Last quote about Amgen

Karen Linehan - Sanofi
We are pleased with the Federal Circuit's decision to remand for a new trial that allows us to present our complete evidence to the jury. It is our longstanding position that Amgen's asserted patent claims are invalid, and we remain confident in the long-term availability of Praluent for
share this quote
Oct 05 2017
In this page you'll find all points of view published about Amgen. You'll find 61 quotes on this page. You can filter them by date and by a person’s name. You can also see the other popular topics. The 3 people who have been quoted more about Amgen are: Sean E. Harper, Steven Nissen and Joshua Ofman. Sean E. Harper specifically said: “The FDA's decision to grant priority review for the Repatha cardiovascular outcomes data highlights the urgency to address the need to reduce heart attacks and strokes in high-risk patients who struggle to lower their LDL cholesterol. We look forward to working with the FDA to update the label for Repatha enabling us to more broadly educate physicians and patients of the proven impact of Repatha to reduce cardiovascular events.”.
Automatically powered by Storyzy
Take our quote verification challenge and find out !
Geoffrey C. Porges - Leerink Partners

While Amgen's growth products are performing nicely … they don't have enough size to offset the flattening legacy products. The company requires new opportunities to offset the further decline of legacy products, and their late stage pipeline looks embarrassingly

Dan Nathan

Biotech has underperformed [the Nasdaq] for about a year and a half. They just picked up. I think it's important to remember that these stocks move around [on earnings].feedback

Mike Khouw

[Celgene] finally seems like it's starting to move after trading sideways all this time, and right now is a good time to take advantage of options prices being low. This is a way to capture

Carter Worth - Cornerstone Macro

What we know about biotech is it was the leading single place you could be from 2011 to 2015. This is arguably the single best-performing equity over the past 30 years. It's ready to go again, having rested for two or three years. To my eye we are going to explode out to the

Carter Worth - Cornerstone Macro

I think big gains … and a setup for a powerful advance from the No. 1 stock

Sean E. Harper - Amgen

The efficacy results from this study comparing Evenity to an active control are robust. At the same time, the newly observed cardiovascular safety signal will have to be assessed as part of the overall benefit/risk profile for

Hannes Smarason

We are building the world's leading genomic data platform, applying genome sequencing data at scale to improve human health and wellness around the world. Our rapidly expanding business is serving the world's leading precision medicine initiatives as well as genome-driven diagnostics and wellness enterprises

Marc Sabatine

Just like in statin trials the benefit appeared to grow over time. As a clinician this is very big news. We have another tool to significantly reduce heart attacks and stokes. That's a big

Marc Sabatine

Just like in statin trials the benefit appeared to grow over time. As a clinician this is very big news. We have another tool to significantly reduce heart attacks and stokes. As a society we need to move to modifying these risk factors to not only prevent recurrent events but to prevent first

Ronny Gal

At a cost of $7K/year, this translates to $958K per event saved. Thus, in our view, payers will continue to restrict access to the

Mark Hlatky

That's the biggest issue -- whether they're worth all the

Troyen Brennan - CVS Health

I think responsibly, if the number you are treating goes up and you are trying to recoup the cost of (developing) the drug ... one would hope that the price would go

Joshua Ofman - Amgen

In fact, they may even be below the value-based range for the types of patients getting access now. We want to engage payers in risk-sharing contracts. If the drug does not perform, net prices will go down. But if the drug performs as we expect, they will not. Access restrictions have been a real challenge for patients and their

Leslie Cho - Cleveland Clinic

What I care about is there are patients for whom the PCSK9 is absolutely

Jorge Plutzky

Any statistically significant reduction in cardiovascular events would be important to

Jim Cramer

In case President Trump is watching, let me just say I am thrilled that we have such strong hiring in this country, but the fastest way to reverse that trend would be to put through this border tax and watch retailer after retailer either close stores or go out of business. Yes, it would be that

Jim Cramer

If you don't already own it, I would wait. There is always a chance that this time is different, but I know that the sell-off last time was nasty, brutish and short, and it gave you one of the best buying opportunities we have had in

Sean E. Harper - Amgen

Endeavor is the only (relapsed multiple myeloma) study to demonstrate a survival benefit in a head-to-head comparison with a current standard of care

Ying Huang

In light of Trump's proposal on cash repatriation, we believe AMGN could repatriate a significant portion of its $34.8B cash held overseas. The potential share buyback, dividend payment and acquisitions associated with the cash repatriation can further boost stock performance, in our

Richard Francis - Sandoz

[The legal fight] won't really reach a conclusion until 2018. That's the frustration sometimes of the legal situation, but the way I look at that, we're carving the landscape out as we

Len Schleifer - Regeneron Pharmaceuticals

To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't

Len Schleifer - Regeneron Pharmaceuticals

If this industry is to survive, we have got to do the right thing by patients … and still adequately reward our

Len Schliefer

To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't beloved. If this industry is to survive, we have got to do the right thing by patients ... and still adequately reward our

Jim Cramer

I think Amgen can go much higher, perhaps on comments coming out of this healthcare

Michael Yee - RBC Capital Markets

If Praluent was gone from the market the long-term peak sales for Repatha could move from $2 billion to $3 billion to $4 billion worldwide, in

Karen Linehan - Sanofi

We will immediately appeal today's ruling, along with the jury's earlier finding upholding the validity of Amgen's patents. It is our longstanding position that Amgen's patent claims are invalid and that the best interests of patients will be greatly disserved by an injunction preventing access to

Kristen Davis - Amgen

The court's ruling today is an important step in this case and confirms the jury's finding that the patents which protect Repatha are valid and infringed by

Ashleigh Koss - Sanofi

It is our longstanding position that Amgen's asserted patent claims are invalid, and we intend to appeal today's

Randy Shultz

We've got 13 million candidate patients ... and at least initially there will be four drugs addressing what is five times as many patients (as the RA market). We would argue that each of these drugs has the potential to be a blockbuster alongside each

Charles Duncan - Piper Jaffray

Migraine today can be characterized as similar to RA in the past, in that it's a large but under-treated, and also under-diagnosed, market. The burden of disease in terms of patient quality of life, function, and resource utilization is also high. Because of these market dynamics, there is likely room for multiple agents - even of the same mechanism - to be

Stephen Nicholls

These findings suggest that the large clinical outcome trials currently underway are likely to show major

Seth Baum

It's crazy what's going on. They've basically destroyed our capacity to treat our patients with the drugs that we need to treat them

Steven Nissen - Cleveland Clinic

That's unbelievable. So when you get down to 24 you've got a really high chance of your plaques melting

Steven Nissen - Cleveland Clinic

We didn't know what would happen to disease progression at LDL cholesterol levels when we go to below about

Richard Francis - Sandoz

The realization of what it's going to take to stay in this market and be successful has led to a change in the landscape and the players in

Michael Nawrath

It's not like these companies are bitter enemies. These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their

Vasant Narasimhan - Novartis

Our focus has been continuing to generate the data and convince physicians that it's worth making the switch. Now you have data out to four years showing we've maintained the efficacy, at the levels that we saw after year

Andrzej Jakubowiak

This was the wrong combination chosen for this evaluation, wrong duration of treatment as well, which we now know and is potentially

Vasant Narasimhan - Novartis

These important data further support the efficacy of AMG 334 in patients who currently have limited therapeutic

Carol Lynch - Novartis

We are committed to bringing Erelzi to the U.S. market as soon as

David Seaburg - Cowen and Company

We are seeing something occur very different on the desk here. We're seeing people versus selling every rally, or shorting every rally, coming in now and buying every dip. We're seeing a big sentiment shift in general; people getting very comfortable, and that's mainly right after a lot of big-cap names have reported good quarters, decent

Chad Morganlander

We believe that you're going to see consistent revenue growth, as well as improvement within operating margins over the next three to five

Sean E. Harper - Amgen

Migraine is the sixth leading cause of disability worldwide. Three to seven million Americans spend more than half of each month living with the debilitating symptoms of chronic

Tim Race - Deutsche Bank

A permanent injunction is unlikely. However, the likelihood of settlement has now increased substantially with Sanofi and its partner Regeneron potentially forced to pay

Jay Siegel

Only direct clinical comparisons of (Remsima) and Remicade in active irritable bowel disease can provide the requisite

Robert A. Bradway - Amgen

We remain on track to meet or exceed our 2018 commitments and deliver value for patients and

No quotes...
|< <
> >|

Quotes about Amgen

Quote Verifier
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided

Quote :

Mistake :

Comments :